Molecular Vision 2021; 27:370-383 <>
Received 02 December 2020 | Accepted 13 June 2021 | Published 15 June 2021

Amniotic membrane conditioned medium (AMCM) reduces inflammatory response on human limbal myofibroblast, and the potential role of lumican

Alfredo Domínguez-López,1,2 Fátima Sofía Magaña-Guerrero,1 Beatriz Buentello-Volante,1 Luis Antonio Bautista-Hernández,1 Juan Pablo Reyes-Grajeda,3 Víctor Manuel Bautista-de Lucio,1 Yonathan Garfias1,4

1Research Unit, Institute of Ophthalmology Conde de Valenciana Foundation, Mexico City, Mexico; 2Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France; 3Medical Proteomics Unit, Instituto Nacional de Medicina Genómica, Mexico City, Mexico; 4Department of Biochemistry, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico

Correspondence to: Yonathan Garfias, Department of Biochemistry, Faculty of Medicine Universidad Nacional Autónoma de México, Avenida Universidad 3000, 04510, Mexico City, Mexico; Phone: +52(55) 56232168; email:;


Purpose: Viral infections such as herpetic keratitis (HSK) activate the innate immune response in the cornea triggering opacity and loss of vision. This condition is performed mainly by myofibroblasts that exacerbate secretion of inflammatory cytokines. Amniotic membrane transplantation (AMT) reduces ocular opacity and scarring inhibiting secretion of inflammatory cytokines and proliferation of myofibroblasts. We previously reported that the amniotic membrane (AM) favors an anti-inflammatory microenvironment inhibiting the secretion of inflammatory cytokines, expression of innate immune receptors, and translocation of nuclear NF-κB on human limbal myofibroblasts (HLMs). The aim of the present study was to determine whether the soluble factors of the AM decrease the immune response of HLMs stimulated with polyinosinic-polycytidylic acid sodium salt (poly I:C).

Methods: The AM was incubated in Dulbecco's modified eagle medium (DMEM)/F12, and the supernatant was collected to obtain amniotic membrane conditioned medium (AMCM). HLMs were isolated from cadaveric sclera-corneal rims. HLMs were cultured in DMEM/F12 or AMCM and stimulated or not with poly I:C (10 µg/ml) for 12 h to analyze synthesis of CCL2, CCL5, CXCL10, MDA5, RIG-1, and TLR3 or for 2 h to analyze translocation of nuclear NF-kB, IRF3, and IRF7. The proteins contained on AMCM were analyzed by matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), and the acquired peptide ions were analyzed with the Mascot program using both National Center for Biotechnology Information (NCBI) and expressed sequence tag (EST) databases.

Results: AMCM downregulated the mRNA levels of CCL2, CCL5, CXCL10, MDA5, RIG-1, and TLR3. In addition, AMCM decreased secretion of CCL2, CCL5, and CXCL10 and translocation of nuclear NF-κB. Interestingly, AMCM increased translocation of nuclear IRF3 and synthesis and secretion of type I IFN-β. We also identified small leucine-rich proteoglycan lumican in the AMCM. The administration of rh-lumican to poly I:C–stimulated HLMs reduced the mRNA levels of CCL2, CCL5, and CXCL10.

Conclusions: These results suggest that the AM can trigger an anti-inflammatory response on HLMs through soluble factors, and that lumican could play an important role in these effects.


The cornea is considered an immune privileged tissue due to control of the immune response that preserves corneal transparency. However, viral infections such as herpetic keratitis (HSK) induce exacerbation of the immune response that reduces optical clarity and visual acuity [1]. Viral recognition in the cornea is performed mainly by pattern recognition receptors (PRRs) expressed in epithelial cells [2]. After viral recognition, signaling pathways are triggered leading to activation of interferon regulatory factors (IRFs) and nuclear factor-κB (NF-κB). Translocation of nuclear IRFs induces expression of type I interferons (IFNs); translocation of nuclear NF-κB stimulates expression of inflammatory cytokines [3]. The inflammatory microenvironment in corneal stroma promotes differentiation of quiescent keratocytes to fibroblasts and subsequently, to myofibroblasts [4]. Myofibroblasts play a key role in exacerbation of corneal opacity and inflammation. These cells increase the secretion of collagen and chemokines that induce corneal stroma disorganization and stimulate the recruitment of immune cells [5,6].

Cumulative evidence has shown that amniotic membrane transplantation (AMT) is beneficial in many ocular pathologies [7]. Currently, AMT is successfully used to treat HSK and persistent corneal ulcers due to its anti-inflammatory properties [8,9]. The amniotic membrane (AM) is the inner layer of the placenta that is in contact with the amniotic fluid and the fetus. It has been reported that the AM inhibits inflammation suppressing activation and inducing apoptosis of immune cells [10], downregulating synthesis and secretion of proinflammatory cytokines from peripheral blood mononuclear cells [11], and inhibiting innate immune receptors on human limbal myofibroblasts (HLMs) [12]. Additionally, the AM can inhibit TGF-β secretion and reduces differentiation of limbal myofibroblasts, allowing accurate corneal wound healing [13].

The AM is composed of a single epithelial cell layer, a thick basement membrane, and an avascular extracellular matrix [14]. Previous studies have described that the AM matrix possesses different bioactive compounds, such as proteoglycans, fibronectin, laminin, hyaluronic acid (HA), numerous growth factors, cytokines, chemokines, and metalloproteases, among many others, that are proposed to be involved in therapeutic effects of the AM [15-17]. Different studies have reported that the AM secretes soluble factors with immunosuppressive activities on innate and adaptive immune cells, such as neutrophils, macrophages, and T cells [18-20]. Furthermore, it was recently reported that AM conditioned medium (AMCM) inhibits proliferation and modulates miRNA expression in hepatocarcinoma cells [21].

We have described that the AM can inhibit synthesis and secretion of proinflammatory cytokines downregulating TLR-3, MDA-5, and RIG-1 through inhibition of translocation of nuclear NF-κB in polyinosinic-polycytidylic acid sodium salt (poly I:C)–stimulated HLMs [12]. Whether the activities described above regarding poly I:C–stimulated HLMs are due to soluble AM-secreted factors is still unknown. Therefore, the aim of the present study was to evaluate the effect of soluble factors from AMCM on poly I:C–stimulated HLMs and to identify a soluble factor responsible for the anti-inflammatory effect.



The study was approved by the Institutional Review Board of the Institute of Ophthalmology Conde de Valenciana. Fetal bovine serum (FBS), DMEM/F12, 0.25% trypsin-0.5% EDTA, dispase II, and collagenase II were purchased from Gibco (Waltham, MA). Twenty-four-well cell culture plates and cell culture flasks were obtained from Corning (Corning, NY). RNeasy Mini Kit and the Omniscript RT Kit were obtained from Qiagen (Hilden, Germany). KAPA2G Fast HotStart ReadyMix PCR kit was purchased from Roche (Basilea, Suiza). Polyinosinic-polycytidylic acid sodium salt (poly I:C) was obtained from Invivogen (San Diego, CA). Cytometric Bead Array (CBA) human chemokine Kit was purchased from BD Biosciences (San Diego, CA). Purified rabbit anti-NF-κB, anti-phospho-NF-κB (Ser 536), anti-IRF3, anti-phospho-IRF3 (Ser 386), anti-IRF7, and anti-phospho-IRF7 (Ser 477) antibodies were obtained from Abcam (Cambridge, England). AlexaFluor 488 conjugated-goat anti-rabbit antibody was obtained from Life Technologies (Carlsbad, CA). AmiconUltra-15 centrifugal filter devices were obtained from Millipore (Burlington, MA). The Human IFN-β Enzyme-Linked Immunosorbent Assay (ELISA) kit was obtained from PBL Assay Science (Piscataway, NJ). The Human Lumican DuoSet ELISA Kit (Minneapolis, MN) and recombinant human (rh)-lumican protein were purchased from R&D Systems (Minneapolis, MN). Vectashield-4′, 6-diamidino-2-phenylindole (DAPI) was obtained from Vector Laboratories (Burlingame, CA). Other reagents were obtained from Sigma-Aldrich (St. Louis, MO), unless otherwise stated.

Isolation of HLMs

The HLMs were isolated from cadaveric sclera-corneal rims as we previously described [12]. Briefly, the tissues were incubated with Dispase II (1.7 IU/ml) for 1 h at 37 °C to remove the epithelial cells. The remaining tissue was digested with Collagenase II (0.75 mg/ml) for 18 h at 37 °C. The cells were pooled out with centrifugation at 200 ×g for 5 min at 4 °C and cultured with DMEM/F12 supplemented with 10% FBS at 37 °C, with an atmosphere of 5% CO2. All experiments were performed at two to four passages.

Preparation of AMCM

The AM was obtained after elective cesarean section with informed consent from the donor and was preserved at −80 °C until use as previously reported [7]. After thawing, the AM was de-epithelized by incubating with Dispase II (1.7 IU/ml) for 30 min at 37 °C; then, the epithelium was gently removed using a rubber policeman (denuded AM [dAM]). The complete AM de-epithelialization was corroborated in an inverted microscope. Fifty mg of denuded AM (dAM) were incubated in one ml of DMEM/F12 medium during 4 h at 37 °C. After the incubation period, the supernatant was collected diluted at 40% (v/v) with fresh medium and immediately used.

Cell culture conditions

The HLMs (1 × 105 cells per well) were seeded on a 24-well cell culture plate for 12 h in the presence of 10% FBS-supplemented medium to allow their adherence to the plate. Afterward, the cells were FBS starved for 12 h and stimulated or not with poly I:C (10 µg/ml) for 12 h in the presence or not of AMCM. The cytokines secreted from the HLMs exposed to different conditions were measured in the supernatants. Similarly, to analyze translocation of nuclear NF-κB, IRF3, and IRF7, the cells were adhered in poly-L-lysine coated coverslips for 12 h in the presence of 10% FBS-supplemented medium. Thereafter, the cells were FBS starved for 12 h and stimulated or not with poly I:C (10 µg/ml) for 120 min in the presence or not of AMCM.

Identification of transcripts

The HLM exposed to different stimuli were harvested and total RNA was obtained using the RNeasy Mini Kit as indicated by the manufacturer. RNA quality and concentration were measured by the NanoDrop method (Thermo Scientific, Labtech, Uckfield, England). Reverse transcription was performed with 100 ng of RNA using the Omniscript RT Kit according to the manufacturer's instructions. Quantitative PCR was performed using KAPA2G Fast HotStart ReadyMix PCR kit and primers in a final volume of 20 μl according to the manufacturer's instructions. Specific mRNA levels were calculated after normalization of the results for each sample with those for β2-microglobulin (β2m) mRNA. The 2−ΔΔCt method was used to analyze the relative differences in specific mRNA levels between groups. All the assays were performed three times in triplicate.

Measurement of chemokines

The supernatants from the HLMs exposed to different stimuli were collected to measure chemokine secretion using the CBA Human Chemokine Kit according to the manufacturer’s instructions. The data were acquired in a BD FACSVerse flow cytometer, and analyses were performed using the BD FCAP Array v3.0 software. The results were based on a standard concentration curve and expressed as picograms per milliliter. All assays were performed three times in triplicate.

Immunofluorescence staining

HLMs seeded on coverslips were exposed to the stimuli above and used to identify the translocation of nuclear transcription factors, as well as to determine their phosphorylation form, with immunofluorescence staining assays. Briefly, the cells were fixed with 4% p-formaldehyde for 10 min at 4 °C and washed with PBS (1X; 120 mM NaCl, 20 mM KCl, 10 mM NaPO4, 5 mM KPO4, pH 7.4). Afterwards, the cells were incubated with blocking buffer (0.5% TritonX-100, 5% BSA in PBS) for 1 h at 4 °C. The cells were incubated with primary antibodies: NF-κB, phosphoNF-κB (pNF-κB), IRF3, phosphoIRF3 (pIRF3), IRF-7 or phosphoIRF7 (pIRF7) at 4°C overnight. After washing with PBS, the coverslips were incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG for 2 h at 4 °C. Finally, the cells were washed three times with PBS, mounted with Vectashield-DAPI, observed with an ApoTome II microscope, and analyzed using Axiovison software (Carl Zeiss, Jena, Germany). The protein identification analyses were performed as previously described [22,23] with slight modifications. Briefly, the background signal was adjusted in all images assessed using the same magnification, identifying the nuclear and non-nuclear compartments, and the mean fluorescence intensity was achieved using ImageJ.

Quantification of IFN-β

The supernatants from the HLMs exposed to different stimuli were collected to measure secreted IFN-β using the human IFN-β ELISA kit following the manufacturer’s instructions. Results were acquired with a Multiskan Ascent spectrophotometer (Thermo Fisher Scientific, Waltham, MA) at 450 nm wavelength. The assays were performed three times in triplicate.

Enzymatic treatment of AMCM

To determine whether the possible factors with bioactivity were proteins, AMCM was incubated or not with proteinase K (10 µg/ml) for 50 min at 37 °C. After protein digestion, the AMCM was boiled for 5 min to inactivate proteinase K and was used immediately.

Isolation of proteins

AMCM was concentrated using the Amicon centrifugal filter device, and the proteins were resolved in denaturing sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE). Briefly, 10 ml of AMCM was added to the filter device and centrifuged at 4,000 ×g for 30 min at 4 °C. Afterward, 200 μl of AMCM (50X concentrated) was obtained and resolved in a denaturing 4%–20% SDS–PAGE. Proteins were stained with Coomassie blue.

Identification of proteins

The proteins contained on AMCM were analyzed with mass spectrometry matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) as previously reported [24]. Briefly, the protein bands were removed from the SDS–PAGE with a sterile scalpel and washed with 50% (v/v) acetonitrile in 25 mM ammonium bicarbonate for 15 min twice to remove the Coomassie dye. After dehydration with 100% (v/v) acetonitrile for 10 min at 25 °C, the gel pieces were vacuum-dried and rehydrated with sequencing-grade modified trypsin (Promega, Madison, WI) in 25 mM ammonium bicarbonate at 37 °C overnight. The in-gel tryptic digested samples were injected into an integrated nano-high performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry and electrospray ionization (HPLC-ESI-MS/MS) system (quadrupole/time of flight; Ultima API, Micromass, Manchester, UK). After dissolving with 0.1% formicacid, the samples were loaded into an analytical C18 capillary column connected online to the mass spectrometer. Instrumental operation, data acquisition, and analysis were performed under the full control of Mass-Lynx 4.0 (Micromass). The 1-s survey scans were run over the mass range of m/z 400 to 2000. A maximum of three concurrent MS/MS acquisitions were triggered for 2þ, 3þ, and 4þ charged precursor detection at an intensity above the predefined threshold. The acquired peptide ions were analyzed with the Mascot program using the NCBI and EST databases.

Lumican quantification with ELISA

AMCM was used to measure lumican using the Human Lumican DuoSet ELISA kit, following the manufacturer’s instructions. Results were obtained with a spectrophotometer at 450 nm wavelength. All assays were performed three times in triplicate.

rh-Lumican assays

The HLMs were cultured and exposed to different doses (2.5, 5.0, or 10 ng/ml, unless otherwise stated) of rh-lumican to analyze its effect on morphology of HLMs and synthesis of proinflammatory cytokines with inverted microscopy and transcripts analysis, respectively. All assays were performed three times in triplicate.

Statistical analysis

Data were assessed with one-way analysis of variance (ANOVA) followed by Bonferroni correction test. The data were expressed as mean ± standard error of the mean (SE), and p values of less than 0.05 were considered statistically significant. All statistics were performed using GraphPad Prism 5 software (GraphPad, La Jolla, CA).


AMCM inhibited synthesis and secretion of chemokines and decreased synthesis of innate immune receptors in poly I:C–stimulated HLMs

In a previous report, we described that dAM inhibited the immune response of poly I:C–stimulated HLMs. However, it was not clear whether this effect was due to HLM-dAM contact or to the soluble factors released from dAM [12]. Consequently, poly I:C–stimulated HLMs were incubated in the presence of AMCM, and synthesis of the chemokines was evaluated. AMCM decreased RNA synthesis of CCL2, CCL5, and CXCL10. In addition, when the supernatants were obtained to measure the secretion of the chemokines, AMCM decreased the CCL2, CCL5, and CXCL10 protein secretion in poly I:C–stimulated HLMs. Additionally, AMCM decreased the expression of the transcripts from innate immune receptors MDA5, RIG-1, and TLR-3 in the poly I:C–stimulated HLMs (Figure 1).

AMCM inhibited translocation of nuclear NF-κB and p-NF-κB in poly I:C–stimulated HLMs

To determine whether the reduction in synthesis and secretion of inflammatory chemokines was associated with changes in activation of NF-κB, NF-κB phosphorylation and translocation of nuclear NF-κB were analyzed. As expected, poly I:C stimulation promoted translocation of nuclear NF-κB, while AMCM clearly inhibited translocation of nuclear NF-κB in poly I:C–stimulated HLMs. Moreover, AMCM decreased the presence of nuclear and cytoplasmic NF-κB and p-NF-κB molecules on poly I:C–stimulated HLMs (Figure 2).

AMCM increased translocation of nuclear IRF3 and synthesis and secretion of IFN-β in poly I:C–stimulated HLMs

To identify whether AMCM exerts an effect in the HLM antiviral response, phosphorylation and translocation of nuclear IRF3 and IRF7 transcription factors were achieved. Interestingly, AMCM increased phosphorylation and translocation of nuclear IRF3 on poly I:C–stimulated HLMs (Figure 3), and increased synthesis and secretion of IFN-β on poly I:C–stimulated HLMs. In contrast, the phosphorylation form and translocation of nuclear IRF7 were not modified by AMCM in the poly I:C–stimulated HLMs (Figure 4).

The proteinase K treatment on AMCM decreased inhibition of synthesis of chemokines in poly I:C–stimulated HLMs

We analyzed the activity of AMCM treated with proteinase K to evaluate the nature of soluble factors responsible for the anti-inflammatory response in poly I:C–stimulated HLMs. AMCM treated with proteinase K inhibited the capacity to decrease synthesis of CCL2, CCL5, and CXCL10 chemokines on poly I:C–stimulated HLMs (Figure 5). These results suggest that AMCM soluble factors with anti-inflammatory properties are partly protein.

Lumican was identified in AMCM

To identify the protein or proteins released from dAM, AMCM was 50 times concentrated and resolved in SDS–PAGE under reducing conditions. A strong band between 25 and 35 kDa was detected in comparison with AMCM treated with proteinase K (AMCM+PK, Figure 6). This band was isolated and analyzed with mass spectrometry, and the Mascot program identified one protein (Figure 6). This protein corresponded to small leucine-rich proteoglycan lumican with a 38 kDa core protein [25]. The presence of lumican in AMCM was corroborated with ELISA in which we determined a concentration of 10 ng/ml.

rh-Lumican decreased synthesis of the CCL2, CCL5, and CXCL10 in poly I:C–stimulated HLMs

To identify whether lumican exerts similar effects to those obtained with AMCM on HLMs, poly I:C–stimulated HLMs were incubated with different doses (1.0, 2.5, and 5.0 ng/ml) of rh-lumican. Interestingly, when the poly I:C–stimulated HLMs were cultured with rh-lumican, and RT–PCR assays were performed, there were significant reductions in synthesis of CCL2, CCL5, and CXCL10 in comparison with the poly I:C–stimulated HLMs without rh-lumican (Figure 7).


During corneal disruption, the inflammatory microenvironment in the ocular surface induces activation of fibroblasts exacerbating corneal opacity and scarring [26,27]. Corneal fibroblasts lead the immune response in the ocular surface through chemoattraction of immune cells and induction of inflammation. These conditions promote differentiation of these cells into myofibroblasts increasing proinflammatory cytokines and abnormal secretion of extracellular matrix proteins [5,28].

We previously reported that the AM exerts its beneficial properties modulating the innate immune response on HLMs [12]. Moreover, the AM induces an antiscarring environment, which is associated with reduction in fibrosis in the tissue [10,29,30]. It has been suggested that AM soluble factors inhibit the TGF-β signaling pathway and α-SMA expression in corneal myofibroblasts decreasing their activity and proliferation [31,32], which favors correct corneal healing.

Several studies have suggested that the AM stroma release several soluble factors, such as IL-10, IL-1RA, and IαI, among many others, with the capacity to modulate the inflammatory response in the ocular surface F. In this report, we suggest that the soluble factors of the AM have the ability to modulate the anti-inflammatory and antiviral response of HLMs. The synthetic analog of double-stranded RNA poly I:C increased the synthesis and secretion of the proinflammatory chemokines CCL2, CCL5, and CXCL10 in HLMs; however, when the cells were poly I:C stimulated in the presence of AMCM, the synthesis and secretion of these chemokines were abolished significantly. AMCM did not affect the cell morphology or induce any HLM detachment (data not shown). Therefore, the decrease in synthesis and secretion of the chemokines observed was due to an immunomodulatory process [11] intrinsic to HLMs instead of the possible decrease in the cell number attached to the plate or an accelerated apoptosis. To understand inhibition of synthesis and secretion of these proinflammatory proteins, we investigated the dynamics of NF-κB. In this context, it is known that inhibition of translocation of nuclear NF-κB reduces expression of proinflammatory cytokines, chemokines, and adhesion molecules in human corneal fibroblasts [33-35]. In this study, we showed that soluble factors of AMCM significantly reduced the presence of cytoplasmic and nuclear NF-κB as well as inhibited translocation of nuclear NF-κB in poly I:C–stimulated HLMs. These results indicate that inhibition of NF-κB activity decreased synthesis and secretion of CCL2, CCL5, and CXCL10, mediated by soluble factors contained in AMCM [36]. Similarly, AMCM was able to reduce synthesis of innate immune receptors TLR3, RIG-1, and MDA5; this result is in accordance with our preceding report [12], indicating that AMCM is able to reduce the innate immune response at the transcription level.

IRFs are transcription factors involved in expression of IFN-α/β and IFN-inducible genes that activate the antiviral response [37]. Interestingly, the soluble factors contained in AMCM significantly induced translocation of nuclear IRF3 and p-IRF3 which was associated with an increase in synthesis and secretion of IFN-β in poly I:C–stimulated HLMs, suggesting that soluble factors in AMCM increase the antiviral response of HLMs. This effect could be partially responsible for the beneficial outcomes of use of the AM for treatment of many ocular surface diseases, including HSK. It has been reported that the AM exerts an antimicrobial effect due to the presence of antimicrobial peptides [38-40]. Moreover, it has been suggested that the AM exerts an antiviral effect with the secretion of TNF-α, IFN-α, IFN-β, and IFN-γ constitutively presented in the membrane stroma [41]; however, the antiviral properties of the AM are still under study.

As described, the AM has the capability to release several soluble factors that could explain its anti-inflammatory, antiscarring, and antiviral properties [41,42]. In this study, we showed that treatment with proteinase K significantly reduces the anti-inflammatory effect of AMCM, which could indicate that the effect is due in part to proteins released from the AM. The mass spectrometry analysis and ELISA identified the proteoglycan lumican in AMCM [25]. Lumican is a small leucine-rich proteoglycan abundantly present in the stromal matrix of different tissues, such skeletal muscle, lung, liver, and cornea [43]. Interestingly, the proteome profile of the AM was described previously, and lumican was identified as one of the most abundant proteins in the AM stroma [44,45]. Moreover, lumican purified from the AM stromal matrix topically applied in mice with corneal de-epithelialization was able to ameliorate re-epithelialization inducing migration and proliferation of corneal cells [46]. In this context, in addition to the immunosuppressive activities exerted by lumican shown in the present study, it has been described that lumican directly binds to TGF-βR1 and promotes wound healing in corneal epithelial cells [47]. Thus, AM-derived lumican might possess dual activity in healing of ocular surface diseases.

In the present study, we showed that lumican reduced synthesis of chemokines such as CCL2, CCL5, and CXCL10 in poly I:C–stimulated HLMs. These results are consistent with other studies suggesting the anti-inflammatory role of lumican in other models. The functions of lumican include regulation of corneal inflammatory responses by inducing apoptosis of inflammatory cells [48], inhibition of proliferation and migration of melanoma cells through alteration of actin filaments and focal adhesion complexes [49], inhibition of adhesion of cancer cells, and angiogenesis of umbilical venules by blocking adhesion of α2β1 integrins [50,51]. In accordance with those studies, we found that lumican modulates the inflammatory response of HLM; however, the signaling and molecular mechanisms involved are still unknown. Nevertheless, although we propose lumican as a soluble factor released from the AM that showed immunomodulatory properties, we cannot rule out the presence of multiple soluble factors secreted from the AM, which are still found even when the tissue is cultured, including great variability of cytokines and growth factors [52,53]. Therefore, lumican is partially responsible for these effects in in vitro conditions. Lee et al. previously reported that AMCM induced expression of insulin-like growth factor-1 in human corneal epithelial cells inducing their proliferation [54]; therefore, a similar effect of AMCM on HLMs cannot be discarded. Finally, it has been described that amniotic membrane suspension and amniotic membrane homogenate exert proliferation and migration activities on human corneal epithelial cells [55]; thus, AMCM could be beneficial in ocular cell surface diseases promoting corneal epithelialization and diminishing local inflammation process.

Taking all these data together, we can point out that lumican is an important factor of the AM that possesses anti-inflammatory properties. These in vitro findings correlate in part with the biologic properties of amniotic membrane transplantation. However, studies validating AM-secreted lumican as a potential molecule to treat ocular surface diseases are needed.


  1. Park PJ, Chang M, Garg N, Zhu J, Chang JH, Shukla D. Corneal lymphangiogenesis in herpetic stromal keratitis. Surv Ophthalmol. 2015; 60:60-71. [PMID: 25444520]
  2. Biswas PS, Rouse BT. Early events in HSV keratitis–setting the stage for a blinding disease. Microbes Infect. 2005; 7:799-810. [PMID: 15857807]
  3. Ma Y, He B. Recognition of herpes simplex viruses: toll-like receptors and beyond. J Mol Biol. 2014; 426:1133-47. [PMID: 24262390]
  4. Hinz B. Myofibroblasts. Exp Eye Res. 2016; 142:56-70. [PMID: 26192991]
  5. Shu DY, Lovicu FJ. Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis. Prog Retin Eye Res. 2017; 60:44-65. [PMID: 28807717]
  6. Raghunathan VK, Thomasy SM, Strom P, Yanez-Soto B, Garland SP, Sermeno J, Reilly CM, Murphy CJ. Tissue and cellular biomechanics during corneal wound injury and repair. Acta Biomater. 2017; 58:291-301. [PMID: 28559158]
  7. Chavez-Garcia C, Jimenez-Corona A, Graue-Hernandez EO, Zaga-Clavellina V, Garcia-Mejia M, Jimenez-Martinez MC, Garfias Y. Ophthalmic indications of amniotic membrane transplantation in Mexico: an eight years Amniotic Membrane Bank experience. Cell Tissue Bank. 2016; 17:261-8. [PMID: 26675894]
  8. Roozbahani M, Hammersmith KM. Management of herpes simplex virus epithelial keratitis. Curr Opin Ophthalmol. 2018; 29:360-4. [PMID: 29697435]
  9. Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014; 8:571-9. [PMID: 24672223]
  10. Solomon A, Wajngarten M, Alviano F, Anteby I, Elchalal U, Pe’er J, Levi-Schaffer F. Suppression of inflammatory and fibrotic responses in allergic inflammation by the amniotic membrane stromal matrix. Clin Exp Allergy. 2005; 35:941-8. [PMID: 16008682]
  11. Garfias Y, Zaga-Clavellina V, Vadillo-Ortega F, Osorio M, Jimenez-Martinez MC. Amniotic membrane is an immunosuppressor of peripheral blood mononuclear cells. Immunol Invest. 2011; 40:183-96. [PMID: 21080833]
  12. Dominguez-Lopez A, Bautista-de Lucio VM, Serafin-Lopez J, Robles-Sanchez E, Garfias Y. Amniotic membrane modulates innate immune response inhibiting PRRs expression and NF-kappaB nuclear translocation on limbal myofibroblasts. Exp Eye Res. 2014; 127:215-23. [PMID: 25117451]
  13. Tseng SC, Espana EM, Kawakita T, Di Pascuale MA, Li W, He H, Liu TS, Cho TH, Gao YY, Yeh LK, Liu CY. How does amniotic membrane work? Ocul Surf. 2004; 2:177-87. [PMID: 17216089]
  14. Litwiniuk M, Grzela T. Amniotic membrane: new concepts for an old dressing. Wound Repair Regen. 2014; 22:451-6. [PMID: 25041617]
  15. He H, Kuriyan AE, Su CW, Mahabole M, Zhang Y, Zhu YT, Flynn HW, Parel JM, Tseng SC. Inhibition of Proliferation and Epithelial Mesenchymal Transition in Retinal Pigment Epithelial Cells by Heavy Chain-Hyaluronan/Pentraxin 3. Sci Rep. 2017; 7:43736 [PMID: 28252047]
  16. Lei J, Priddy LB, Lim JJ, Massee M, Koob TJ. Identification of Extracellular Matrix Components and Biological Factors in Micronized Dehydrated Human Amnion/Chorion Membrane. Adv Wound Care (New Rochelle). 2017; 6:43-53. [PMID: 28224047]
  17. Litwiniuk M, Radowicka M, Krejner A, Sladowska A, Grzela T. Amount and distribution of selected biologically active factors in amniotic membrane depends on the part of amnion and mode of childbirth. Can we predict properties of amnion dressing? A proof-of-concept study. Cent Eur J Immunol. 2018; 43:97-102. [PMID: 29731692]
  18. Witherel CE, Yu T, Concannon M, Dampier W, Spiller KL. Immunomodulatory Effects of Human Cryopreserved Viable Amniotic Membrane in a Pro-Inflammatory Environment In Vitro. Cell Mol Bioeng. 2017; 10:451-62. [PMID: 29225709]
  19. Li H, Niederkorn JY, Neelam S, Mayhew E, Word RA, McCulley JP, Alizadeh H. Immunosuppressive factors secreted by human amniotic epithelial cells. Invest Ophthalmol Vis Sci. 2005; 46:900-7. [PMID: 15728546]
  20. Shao C, Sima J, Zhang SX, Jin J, Reinach P, Wang Z, Ma JX. Suppression of corneal neovascularization by PEDF release from human amniotic membranes. Invest Ophthalmol Vis Sci. 2004; 45:1758-62. [PMID: 15161837]
  21. Riedel R, Perez-Perez A, Carmona-Fernandez A, Jaime M, Casale R, Duenas JL, Guadix P, Sanchez-Margalet V, Varone CL, Maymo JL. Human amniotic membrane conditioned medium inhibits proliferation and modulates related microRNAs expression in hepatocarcinoma cells. Sci Rep. 2019; 9:14193 [PMID: 31578445]
  22. Ververis K, Marzully S, Samuel CS, Hewitson TD, Karagiannis TC. Qualitative and Quantitative Analysis of Histone Deacetylases in Kidney Tissue Sections. Methods Mol Biol. 2016; 1397:279-89. [PMID: 26676140]
  23. Schwenzer H, Juhling F, Chu A, Pallett LJ, Baumert TF, Maini M, Fassati A. Oxidative Stress Triggers Selective tRNA Retrograde Transport in Human Cells during the Integrated Stress Response. Cell Reports. 2019; 26:3416-28. [PMID: 30893612]
  24. Bautista-de Lucio VM, Lopez-Espinosa NL, Robles-Contreras A, Perez-Cano HJ, Mejia-Lopez H, Mendoza G, Jimenez-Martinez MC, Garfias Y. Overexpression of peroxiredoxin 2 in pterygium. A proteomic approach. Exp Eye Res. 2013; 110:70-5. [PMID: 23499777]
  25. Pilling D, Vakil V, Cox N, Gomer RH. TNF-alpha-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation. Proc Natl Acad Sci USA. 2015; 112:11929-34. [PMID: 26351669]
  26. Tsatsos M, MacGregor C, Athanasiadis I, Moschos MM, Hossain P, Anderson D. Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents. Clin Experiment Ophthalmol. 2016; 44:824-37. [PMID: 27273328]
  27. Fukuda K, Ishida W, Fukushima A, Nishida T. Corneal Fibroblasts as Sentinel Cells and Local Immune Modulators in Infectious Keratitis. Int J Mol Sci. 2017; 181831 [PMID: 28832498]
  28. Pakshir P, Hinz B. The big five in fibrosis: Macrophages, myofibroblasts, matrix, mechanics, and miscommunication. Matrix Biol. 2018; 68–69:81-93. [PMID: 29408013]
  29. Lemke A, Ferguson J, Gross K, Penzenstadler C, Bradl M, Mayer RL, Gerner C, Redl H, Wolbank S. Transplantation of human amnion prevents recurring adhesions and ameliorates fibrosis in a rat model of sciatic nerve scarring. Acta Biomater. 2018; 66:335-49. [PMID: 29191510]
  30. Ricci E, Vanosi G, Lindenmair A, Hennerbichler S, Peterbauer-Scherb A, Wolbank S, Cargnoni A, Signoroni PB, Campagnol M, Gabriel C, Redl H, Parolini O. Anti-fibrotic effects of fresh and cryopreserved human amniotic membrane in a rat liver fibrosis model. Cell Tissue Bank. 2013; 14:475-88. [PMID: 22926336]
  31. Li W, He H, Chen YT, Hayashida Y, Tseng SC. Reversal of myofibroblasts by amniotic membrane stromal extract. J Cell Physiol. 2008; 215:657-64. [PMID: 18181149]
  32. Liu J, Sheha H, Fu Y, Liang L, Tseng SC. Update on amniotic membrane transplantation. Expert Rev Ophthalmol. 2010; 5:645-61. [PMID: 21436959]
  33. Liu Y, Kimura K, Yanai R, Chikama T, Nishida T. Cytokine, chemokine, and adhesion molecule expression mediated by MAPKs in human corneal fibroblasts exposed to poly(I:C). Invest Ophthalmol Vis Sci. 2008; 49:3336-44. [PMID: 18660424]
  34. Lu Y, Fukuda K, Nakamura Y, Kimura K, Kumagai N, Nishida T. Inhibitory effect of triptolide on chemokine expression induced by proinflammatory cytokines in human corneal fibroblasts. Invest Ophthalmol Vis Sci. 2005; 46:2346-52. [PMID: 15980221]
  35. Orita T, Kimura K, Zhou HY, Nishida T. Poly(I:C)-induced adhesion molecule expression mediated by NF-{kappa}B and phosphoinositide 3-kinase-Akt signaling pathways in human corneal fibroblasts. Invest Ophthalmol Vis Sci. 2010; 51:5556-60. [PMID: 20574012]
  36. Choi SS, Lee HJ, Lim I, Satoh J, Kim SU. Human astrocytes: secretome profiles of cytokines and chemokines. PLoS One. 2014; 9:e92325 [PMID: 24691121]
  37. Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol. 2002; 14:111-6. [PMID: 11790540]
  38. Tehrani FA, Modaresifar K, Azizian S, Niknejad H. Induction of antimicrobial peptides secretion by IL-1beta enhances human amniotic membrane for regenerative medicine. Sci Rep. 2017; 7:17022 [PMID: 29208979]
  39. Yadav MK, Go YY, Kim SH, Chae SW, Song JJ. Antimicrobial and Antibiofilm Effects of Human Amniotic/Chorionic Membrane Extract on Streptococcus pneumoniae. Front Microbiol. 2017; 8:1948 [PMID: 29089928]
  40. Mao Y, Hoffman T, Singh-Varma A, Duan-Arnold Y, Moorman M, Danilkovitch A, Kohn J. Antimicrobial Peptides Secreted From Human Cryopreserved Viable Amniotic Membrane Contribute to its Antibacterial Activity. Sci Rep. 2017; 7:13722 [PMID: 29057887]
  41. Paradowska E, Blach-Olszewska Z, Sender J, Jarosz W. Antiviral nonspecific immunity of human placenta at term: possible role of endogenous tumor necrosis factors and interferons. J Interferon Cytokine Res. 1996; 16:941-8. [PMID: 8938570]
  42. Murri MS, Moshirfar M, Birdsong OC, Ronquillo YC, Ding Y, Hoopes PC. Amniotic membrane extract and eye drops: a review of literature and clinical application. Clin Ophthalmol. 2018; 12:1105-12. [PMID: 29950805]
  43. Karamanou K, Perrot G, Maquart FX, Brezillon S. Lumican as a multivalent effector in wound healing. Adv Drug Deliv Rev. 2018; 129:344-51. [PMID: 29501701]
  44. Galera PD, Ribeiro CR, Sapp HL, Coleman J, Fontes W, Brooks DE. Proteomic analysis of equine amniotic membrane: characterization of proteins. Vet Ophthalmol. 2015; 18:198-209. [PMID: 24981051]
  45. Baharvand H, Heidari M, Ebrahimi M, Valadbeigi T, Salekdeh GH. Proteomic analysis of epithelium-denuded human amniotic membrane as a limbal stem cell niche. Mol Vis. 2007; 13:1711-21. [PMID: 17960109]
  46. Yeh LK, Chen WL, Li W, Espana EM, Ouyang J, Kawakita T, Kao WW, Tseng SC, Liu CY. Soluble lumican glycoprotein purified from human amniotic membrane promotes corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2005; 46:479-86. [PMID: 15671272]
  47. Yamanaka O, Yuan Y, Coulson-Thomas VJ, Gesteira TF, Call MK, Zhang Y, Zhang J, Chang SH, Xie C, Liu CY, Saika S, Jester JV, Kao WW. Lumican binds ALK5 to promote epithelium wound healing. PLoS One. 2013; 8:e82730 [PMID: 24367547]
  48. Vij N, Roberts L, Joyce S, Chakravarti S. Lumican regulates corneal inflammatory responses by modulating Fas-Fas ligand signaling. Invest Ophthalmol Vis Sci. 2005; 46:88-95. [PMID: 15623759]
  49. Brezillon S, Radwanska A, Zeltz C, Malkowski A, Ploton D, Bobichon H, Perreau C, Malicka-Blaszkiewicz M, Maquart FX, Wegrowski Y. Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes. Cancer Lett. 2009; 283:92-100. [PMID: 19394140]
  50. Zeltz C, Brezillon S, Kapyla J, Eble JA, Bobichon H, Terryn C, Perreau C, Franz CM, Heino J, Maquart FX, Wegrowski Y. Lumican inhibits cell migration through alpha2beta1 integrin. Exp Cell Res. 2010; 316:2922-31. [PMID: 20705068]
  51. Albig AR, Roy TG, Becenti DJ, Schiemann WP. Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis. 2007; 10:197-216. [PMID: 17632767]
  52. Fitzgerald W, Gomez-Lopez N, Erez O, Romero R, Margolis L. Extracellular vesicles generated by placental tissues ex vivo: A transport system for immune mediators and growth factors. Am J Reprod Immunol. 2018; 80:e12860 [PMID: 29726582]
  53. Bischoff M, Stachon T, Seitz B, Huber M, Zawada M, Langenbucher A, Szentmary N. Growth Factor and Interleukin Concentrations in Amniotic Membrane-Conditioned Medium. Curr Eye Res. 2017; 42:174-80. [PMID: 27314878]
  54. Lee JH, Ryu IH, Kim EK, Lee JE, Hong S, Lee HK. Induced expression of insulin-like growth factor-1 by amniotic membrane-conditioned medium in cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2006; 47:864-72. [PMID: 16505018]
  55. Wu MF, Stachon T, Langenbucher A, Seitz B, Szentmary N. Effect of Amniotic Membrane Suspension (AMS) and Amniotic Membrane Homogenate (AMH) on Human Corneal Epithelial Cell Viability, Migration and Proliferation In Vitro. Curr Eye Res. 2017; 42:351-7. [PMID: 27420558]